Esperion Therapeutics Inc. | Key People and Executives
Tim M. Mayleben
President, Chief Executive Officer & Director
Jeffrey Berkowitz
Independent Director
Nicole Vitullo
Lead Independent Director
Dan S. Janney
Independent Director
Mark E. McGovern
Independent Director
Dov A. Goldstein
Independent Director
Scott N. Braunstein
Independent Director
Antonio M. Gotto
Independent Director
Tim M. Mayleben
President, Chief Executive Officer & Director
Narendra D. Lalwani
COO, Executive VP-Research & Development
Richard B. Bartram
Chief Financial Officer & Secretary
William J. Sasiela
Senior Vice President-Clinical Development
Marianne Andreach
Senior Vice President-Product Planning
Mark A. Glickman
Chief Commercial Officer
Ashley Hall
Senior VP-Global Regulatory Affairs & Policy
Jeffrey Berkowitz
Independent Director
Nicole Vitullo
Lead Independent Director
Dan S. Janney
Independent Director
Mark E. McGovern
Independent Director
Dov A. Goldstein
Independent Director
Scott N. Braunstein
Independent Director
Antonio M. Gotto
Independent Director
| Address |
3891 Ranchero Drive
Ann Arbor Michigan 48108
United States
|
|
Employees
|
- |
| Website |
http://www.esperion.com |
| Updated |
07/08/2019 |
| Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S. |
